Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom's Q2 Loss Narrows 35 Percent as Revenue Rises and R&D Spend Drops

NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
 
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
 
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
 
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.
 
Sequenom said net loss shrank 35 percent to $4 million for the second quarter compared to $6 million last year.
 
Sequenom had $32.6 million in cash and cash equivalents as of June 30. The cash on hand includes the net proceeds of approximately $30 million from a private placement of common stock in June.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.